Hey @Tesla your latest SSD is both terrible and dangerous

DoorDash needs to do a better job of training its drivers in the use of car GPS systems

Are open source pathology models ready for the clinic? Despite significant progress - not quite yet! These models show increased accuracy on retrospective datasets but struggle to deal with real-world variation as outlined on the @arteraAI tech blog: arteraai.medium.com/are-open…

Absolutely true

Founder mode is really just Extreme Ownership (credit @jockowillink ) and should be practiced by everyone, not just the founders

TSA CLEAR is somehow slower than TSA alone. Baffling. Paying extra to go slower is the opposite of product market fit. 🧐

ICYMI: Artera's own @TimShowalter1 was joined by pathologist Adam Cole in an educational webinar sharing how the #ArteraAI Prostate Test works, how it can benefit patients with localized #prostatecancer, & how to start ordering the test. Learn more: heyor.ca/LO2ZFD

The @arteraAI Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patients. To propel adoption, we've integrated with @PathNetLab - a fully digital pathology lab that serves about 10% of the annual US prostate cancer volume across 200 clinics in 27 states. Our test report will now be delivered with immediate turnaround time to clinicians - at the same time as the diagnostic pathology report. This is in addition to being the only predictive test in the @NCCN guidelines, and being reimbursed by @MedicareGov . About 40% of localized prostate cancer patients are NCCN low-risk. In these patients the key clinical decision that needs to be made is whether to put them on active surveillance or active treatment. And if you don't need treatment, you certainly don't want to be placed on it. Artera's test has been updated to help inform clinicians and patients whether they would benefit from active treatment vs surveillance. It is a privilege to work with @PathNetLab and its founder Adam Cole to support prostate cancer patients at scale. Interested clinicians can order our test at artera.ai #prostatecancer #digitalpathology #arteraai #biomarkers #AI #machinelearning #biomarkers #medicalAI businesswire.com/news/home/2…

Boomtown: Austin’s Next Startup Surge in Life Sciences with Jim Breyer (@jimihendrixlive), Thomas Cahill, @AndreEsteva, Jay Hartzell (@JCHartzell), & Claudia Lucchinetti (@LucchinettiMD) Not the next SV or Boston, the first Austin! What’s Next? @UTAustin @DellMedSchool #sxsw

Join us at #UTatSXSW to learn about the next big wave of innovation: life sciences. Recent advances in AI and other technologies have supercharged these fields that will change our lives. utex.as/3uGCm4c #TexasAI | @SXSW